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heterozygotes, 1 homozygous patient); I591T (3 heterozygotes).
Some of them had 2 or more mutations in association. All the pa-
tients were treated with colchicine with a complete (95%) or partial
response to the treatment. None of the patients developed amyloid-
osis. Three patients from unrelated families, had a vasculitis (2 Kawa-
saki Disease; 1 Schoenlein-Hoenoch Purpura) and all presented the
same association: P369S and R408Q.
Conclusion: This finding verifies the importance of molecular diagnosis
and detailed sequencing which is recommended to perform in particu-
lar for the countries with a high risk of FMF.
In several instances, family studies provided the prevalence of a single
mutation in patients experiencing a pathogenic effect, with molecular
evidence for pseudodominant transmission. We evidenced a variable clin-
ical and serological pattern between patients in the same family; the gen-
etic study was in fact extended to parents and brothers of the index
case, with the recommendation to dose Serum amyloid A (SAA), blood
pressure and evaluate an urine analysis to exclude proteinuria.
The M694V homozygous and heterozygous genotype was found to be as-
sociated with a higher prevalence of amyloidosis and arthritis and higher
levels of SAA. The parents of our patients with M694V mutation have more
severe clinical manifestations and a lower response to colchicine.
Further studies are needed to highlight generational differences of
clinical spectrum and SAA levels in FMF patients of the same family,
carrying the same mutations.
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Introduction: Patients with low penetrance mutations for Autoinflam-
matory syndromes (AID) can have severe clinical manifestations, which
require to be treated with biological drugs anti-IL-1.
Objectives: To evaluate the response of AID to treatment with the re-
combinant human IL-1 receptor antagonist anakinra or with the anti-IL-1b.
Methods: We enrolled from 3 centers (U.O. of Rheumatology, Univer-
sitary Hospital “S. Maria Le Scotte”, Siena; S.O.D.C. of Paediatric
Rheumatology, “A. Meyer” Hospital, Florence and U.O. of Paediatric
Clinic, Children Hospital “G. Di Cristina”, Palermo) 26 patients with
SAI and low penetrance mutations, with age: 0.8-58 years (11 M, 15
F; age:4-62 years; medium age of paediatric patients: 11.2 years). The
symptoms started in paediatric age in all the patients; however adult
patients received the diagnosis in adult age.
Results: All the patients (9 CAPS, 10 TRAPS, 2 HIDS, 2 FMF, 3 sJIA) re-
ceived anti-IL-1b drugs (anakinra or canakinumab). The subjects kept a
diary of symptoms at the diagnosis and at the outset, and underwent
clinical and laboratory assessments, including measurement of the SAA,
ESR, CRP, blood count, urinalysis.
At the outset, the 84.6% showed recurrent episodes of fever, variously as-
sociated with: rash (61.5%), abdominal pain (50%), arthralgia and/or myal-
gia (88%), arthritis (46%). All the patients, before starting anti-IL-1b drugs,
were treated with NSAIDs, steroids, DMARDs, colchicine with a poor con-
trol of the disease. The 30.7% associate the anti-IL-1b to one or more of
other drugs. The 57.7% (38.5% between children, 19.2% between adults)
showed a complete remission; the 19.2% incomplete, the 23.1% did not
respond. SAA was increased in 88.5% (M: 155,86; n.v. < 6,4 mg/l), reduced
in 58%. CRP was increased before anti-IL-1b drug in the 50%, with a nor-
mal value in the 92% after the drug was started. ESR was increased in
the 69.2%, with a normal value in the 42.3%.
Proteinuria was detected in the 8% before the anti-IL-1b drug was
started and was in the normal range after they was treated with the
biological drug.
In children, prevalent clinical manifestations were abdominal pain and
arthritis; in adults thorax pain and pericarditis were more frequent.
Conclusion: The clinical features of the AID were correlated with age,
also in patients with low penetrance mutations: some manifestations
were more frequent in adults, others in childhood. The remarkable re-
sponse on clinical and haematological parameters (76.9% of all the
patients) to anakinra or canakinumab suggests that IL-1β has a funda-
mental role in the pathogenesis of inflammation associated with low
penetrance mutations as well. In paediatric age, IL-1 blockade higher ef-
ficacy was probably linked to a more severe clinical phenotype.
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Introduction: Gene TNFRSF1A mutation is linked to TRAPS, autosomal
dominant Autoinflammatory Disease (AID) with recurrent attacks of
fever (2-3 weeks long), abdominal pain, vomiting, serositis, arthralgia
and/or arthritis, myalgia, fasciitis, rash. The disease starts precociously
and amyloidosis is reported in the 25% of the patients. Patients carry-
ing the mutation R92Q usually show a mild clinical phenotype, with an
extreme interindividual variability. Arthralgia and serositis are frequently
less severe, however oral ulcers and pharyngitis are recurrent.
Objectives: We studied the clinical and biochemical impact of the
mutation R92Q in our population and the treatment outcome in all
the patients with clinical relevant symptoms.
Methods: We followed 15 patients (6 M and 9 F), 11 children and 4
adults, carrying the R92Q heterozygous mutation of the gene
TNFRSF1A. The diagnosis of children were done at the age of 4-14
years, o the adults was performed following the sons diagnosis. SAA
levels were significantly high in 8/11 children and in 2/4 adults.
Results: All the symptomatic patients were treated with NSAIDs, ste-
roids, colchicine with a variable control of the disease. The colchicine
was not sufficient in 4/5 patients and 2 of them were treated with
the anti-IL-1 β biological drug canakinumab.
Conclusion: Functional studies performed on R92Q evidenced a
changed conformational structure vs. the wild type.
Our patients showed polymorphic clinical features: some of them are
asymptomatic, other record different symptoms with an intrafamilial
variability. In paediatric age, the clinical phenotype is more severe
also in correlation with the symptoms of parents carrying the same
mutation. We stress the data that all our patients underwent the
genetic study because they recorded symptoms linked to AID.
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Introduction: Priapism, a prolonged penile erection lasting >4 hours, is
a rare condition in childhood. The commonest causes of priapism in
children are sickle cell disease, leukaemia, trauma, idiopathic, and
pharmacologically induced. To date, the association of familial Mediter-
ranean fever (FMF) and priapism has not been reported.
Objectives: To report an FMF patient experiencing priapism during attacks.
Methods: To report an FMF patient experiencing priapism during attacks.
Results: A 20-months-old boy was referred to our pediatric rheumatology
department with the episodes of fever, monoarthritis, and pustules on
the face recurring every month since 10-months of age. Because MEFV
analysis revealed M694V homozygote mutation, he was started 0.25 mg/
day colchicine by his pediatrician when he was 14-months-old. Despite
the adjustment of colchicine to 0.5 mg/day, he continued to have recur-
rent fever and pustules. In his immunologic evaluation, white blood cell
number, immunogobuline G,M,A levels, lymphocyte subgroup disturba-
tion, phagoburst test was normal.He was given a short-course of cortic-
steroid because of fever and a painful erythema nodosum-like lesion
when he was 26-months old. PSTPIP1 mutation was negative for PAPA.
When he was 2.5 years-old, he had penile erection during an attack. Col-
chicine dose was increased to 1 mg/day. He experienced two more at-
tacks of priapism with fever and pustules of the face. He was started an
anti-interleukine 1 treatment, anakinra 1 mg/kg/day. He never had
priapism, pustules, arthritis and fever attacks after the initiation of ana-
kinra. After one year, anakinra was stopped. He is currently taking only
colchicine since one year and doing well.
Conclusion: To the best of our knowledge, this is the first case show-
ing an association of priapism with FMF attacks.
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Introduction: Heterozygous mutations of COPA gene have been re-
cently linked to an autoimmune syndrome characterised by polyarthri-
tis and lung disease with interstitial fibrosis or alveolar haemorrhages
as complication (1). The gene encodes for a regulator of vesicular retro-
grade transport between Golgi and the endoplasmic reticulum (ER). In
most cases the presenting symptoms are cough and tachypnea, that
appear in the early childhood with articular manifestations appearing
lately before di age of 10. At laboratory tests, autoimmunity is charac-
terised by the presence of autoantibodies, with the majority of patients
showing a frankly positive ANA titer (80%). Rheumatoid factor is re-
ported to be raised in 43% of cases; a few patients showed also
positivity for cANCA and pANCA (2).
Objectives: We report one case referring to our centre of a young
girl that presented at 3 year of age with polyarticular arthritis.
Methods: The patient was clinically evaluated by the pediatric
rheumatology unit of Istituto Giannina Gaslini. The family gave per-
mission for publication of clinical and laboratory data and photo-
graphic images as well as molecular analysis.
Results: The patient firstly referred to our centre at 3 year of age for
a polyarticular arthritis involving metacarpophalangeal joints, hip and
cervical spine. Lab results were performed showing raised ESR and
CRP, high titer rheumatoid factor and antinuclear antibodies positivity.
For a newly-onset of a persistent cough with no evidence of infectious
process a chest X-ray and then a lung CT scan was performed showing
an interstitial lung disease with tree-in-a-bud appearance and air-filled
cysts. In order to treat the arthritic process oral and intra-articular
steroids were administered with good response. Methotrexate and aba-
tacept used as steroid-sparing drugs failed to control disease
progression. The molecular analysis of COPA gene showed the reported
c.698G > A mutation. Patient intentionally discontinued therapy for 3
years as well as clinical follow-up. After that time with patient referring
again at our centre, a very severe osteoarthritis with joint damage and
deformities of multiple joints was found.
Conclusion: COPA syndrome could be more common than thought
due the autosomal dominant inheritance. When molecular diagnosis
is confirmed a therapeutic aggressive approach is required to pre-
vent permanent joint deformities and reduce the risk of life threaten-
ing complications such as pulmonary haemorrhages.
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Introduction: Autoinflammatory diseases (AID) are rare in theory;
however with raising awareness their incidence seems to be increas-
ing. Early recognition and appropriate management prevents long-
term sequelae and establishes an improved quality of life.
Objectives: To describe the epidemiology, demographic, clinical
and disease characteristics as well as treatment options in patients with
AID followed up in a national referral center for Pediatric
Rheumatology.
Methods: Cross sectional observational study including thirty-five
children with an AID regularly followed up at “Archbishop Makarios
III” Paediatric Hospital of Nicosia, Cyprus from January 2012 to
date. Children with PFAPA, SJIA and Behcet’s disease were excluded
from this cohort.
Results: Of those 35 children (55% boys), 62% were diagnosed with
mutation proven FMF, 3.5% with TRAPS, 3.5% with HIDS, while the
remaining were classified as a multisystem autoinflammatory disease.
69% of patients were Cypriots, 8% were of Eastern Mediterranean
origin, 8% were Eastern European while the remaining were of mixed
ethnic origin. Mean age at disease onset was 8.4 years (range 0.4 to
17 years). Mean time from disease onset to diagnosis was 1.5 years
(range 0.6 to 3.5 years). Positive family history was evident in 25% of
cases. All patients presented with fever of unknown origin. Other
major symptoms included abdominal pain 65%, diarrhoea 18%, thor-
acic pain 7%, asthenia 27%, weight loss 14%, headache 42%, arthral-
gia and myalgia 23%. Skin manifestations were evident at 21% of
patients; arthritis was present in 27% of patients, 25% of patients de-
veloped serositis (primarily pericarditis) at some point throughout
the course of their disease. Lymph node enlargement was noted in
11%, parotid enlargement in 7%, while 14% had splenomegaly. Uve-
itis was present in 3.4%. Renal involvement was observed in 12% of
our cohort (proteinuria). Renal biopsy was performed on two occa-
sions proving secondary amyloidosis. Oral apthous ulcers were no-
ticed in 15% of patients while hidradenitis suppurativa in 3.5%. The
majority of our patients had received NSAIDS prior to referral; 22%
reported temporal alleviation of their constitutional symptoms. Col-
chicine remained the mainstay of treatment for the majority of these
patients (79%). 67% of these children had received steroids during
the course of their disease. Eight 23% of the patients received
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